The Prevalence and Incidence of Helicobacter pylori-Associated Peptic Ulcer Disease and Upper Gastrointestinal Bleeding Throughout the World

Gastrointestinal Endoscopy Clinics of North America

Volumn 21, Issue 4, 2011, Pages 613-635

  Wang, Andrew Y ^a   Peura, David A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Gastrointestinal bleeding; Helicobacter pylori; Incidence; Peptic ulcer; Prevalence

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CLARITHROMYCIN; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITAZOXANIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RANITIDINE; RIFABUTIN; TETRACYCLINE;

BACTERIAL COLONIZATION; BARRETT ESOPHAGUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; ERADICATION THERAPY; ETHNIC DIFFERENCE; GASTRITIS; GASTRODUODENAL ULCER; HEALTH CARE SYSTEM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MORTALITY; NONHUMAN; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; STOMACH ADENOCARCINOMA; STOMACH ULCER; ULCER HEALING; UNITED STATES; UPPER GASTROINTESTINAL BLEEDING;

DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; PEPTIC ULCER; PREVALENCE; RECURRENCE; STOMACH NEOPLASMS; UNITED STATES; WORLD HEALTH;

EID: 80053185360     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2011.07.011     Document Type: Review

References (130)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994, 272(1):65-69.
2. Goodwin C.S. Nobel prize. BMJ 2005, Available at:, Accessed February 2, 2011. http://www.bmj.com/content/331/7520/795.1/reply.
3. Goodwin C.S., Armstrong J.A., Chilvers T., et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov. respectively. Int J Syst Bacteriol 1989, 39:397-405.
4. Peura D.A., Crowe S.E. Helicobacter pylori. Sleisenger and Fordtran's gastrointestinal and liver disease 2010, 833-845. Saunders, Philadelphia. 9th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
5. Linz B., Balloux F., Moodley Y., et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007, 445(7130):915-918.
6. Kivi M., Tindberg Y. Helicobacter pylori occurrence and transmission: a family affair?. Scand J Infect Dis 2006, 38(6/7):407-417.
7. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000, 22(2):283-297.
8. Amieva M.R., El-Omar E.M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008, 134(1):306-323.
9. Bellack N.R., Koehoorn M.W., MacNab Y.C., et al. A conceptual model of water's role as a reservoir in Helicobacter pylori transmission: a review of the evidence. Epidemiol Infect 2006, 134(3):439-449.
10. De Schryver A.A., Van Hooste W.L., Van Winckel M.A., et al. Helicobacter pylori infection: a global occupational risk for healthcare workers?. Int J Occup Environ Health 2004, 10(4):428-432.
11. Behrman S.W. Management of complicated peptic ulcer disease. Arch Surg 2005, 140(2):201-208.
12. Labenz J., Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994, 55(1):19-23.
13. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122(5):1500-1511.
14. Veldhuyzen van Zanten S.J., Flook N., Chiba N., et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000, 162(Suppl 12):S3-S23.
15. Talley N.J., Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005, 100(10):2324-2337.
16. Sung J.J., Kuipers E.J., El-Serag H.B. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009, 29(9):938-946.
17. Borody T.J., George L.L., Brandl S., et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991, 86(9):1154-1157.
18. Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999, 94(7):1834-1840.
19. Chiorean M.V., Locke G.R., Zinsmeister A.R., et al. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol 2002, 97(12):3015-3022.
20. Longstreth G.F. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995, 90(2):206-210.
21. Gilbert D.A. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc 1990, 36(Suppl 5):S8-S13.
22. van Leerdam M.E., Vreeburg E.M., Rauws E.A., et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003, 98(7):1494-1499.
23. Rockall T.A., Logan R.F., Devlin H.B., et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995, 311(6999):222-226. Clinical research ed.
24. Elmunzer B.J., Young S.D., Inadomi J.M., et al. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol 2008, 103(10):2625-2632. [quiz: 2633].
25. Sanchez-Delgado J., Gene E., Suarez D., et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? a meta-regression. Am J Gastroenterol 2011, 106(3):398-405.
26. Ford A.C., Axon A.T. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010, 15(Suppl 1):1-6.
27. Feinstein L.B., Holman R.C., Yorita Christensen K.L., et al. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis 2010, 16(9):1410-1418.
28. Knowledge about causes of peptic ulcer disease-United States, March-April 1997. MMWR Morb Mortal Wkly Rep 1997, 46:985-987. Centers for Disease Control and Prevention.
29. Schubert M.L., Peura D.A. Control of gastric acid secretion in health and disease. Gastroenterology 2008, 134(7):1842-1860.
30. Morris A., Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987, 82(3):192-199.
31. Graham D.Y., Alpert L.C., Smith J.L., et al. Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol 1988, 83(9):974-980.
32. Ramsey E.J., Carey K.V., Peterson W.L., et al. Epidemic gastritis with hypochlorhydria. Gastroenterology 1979, 76(6):1449-1457.
33. Meyer-Rosberg K., Scott D.R., Rex D., et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996, 111(4):886-900.
34. Kobayashi H., Kamiya S., Suzuki T., et al. The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig. Association with production of vacuolating toxin by H. pylori. Scand J Gastroenterol 1996, 31(5):428-433.
35. Hoffman J.S., King W.W., Fox J.G., et al. Rabbit and ferret parietal cell inhibition by Helicobacter species. Dig Dis Sci 1995, 40(1):147-152.
36. Konturek P.C., Brzozowski T., Karczewska E., et al. Water extracts of Helicobacter pylori suppress the expression of histidine decarboxylase and reduce histamine content in the rat gastric mucosa. Digestion 2000, 62(2-3):100-109.
37. Gooz M., Hammond C.E., Larsen K., et al. Inhibition of human gastric H(+)-K(+)-ATPase alpha-subunit gene expression by Helicobacter pylori. Am J Physiol Gastrointest Liver Physiol 2000, 278(6):G981-G991.
38. Saha A., Hammond C.E., Gooz M., et al. IL-1beta modulation of H, K-ATPase alpha-subunit gene transcription in Helicobacter pylori infection. Am J Physiol 2007, 292(4):G1055-G1061.
39. El-Omar E.M., Oien K., El-Nujumi A., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997, 113(1):15-24.
40. Feldman M., Cryer B., Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol 1998, 274(6 Pt 1):G1011-G1017.
41. Shimatani T., Inoue M., Iwamoto K., et al. Gastric acidity in patients with follicular gastritis is significantly reduced, but can be normalized after eradication for Helicobacter pylori. Helicobacter 2005, 10(3):256-265.
42. El-Omar E.M. Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection. Gut 2006, 55(2):144-146.
43. Derakhshan M.H., El-Omar E., Oien K., et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol 2006, 59(12):1293-1299.
44. Gillen D., el-Omar E.M., Wirz A.A., et al. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998, 114(1):50-57.
45. Moss S.F., Legon S., Bishop A.E., et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992, 340(8825):930-932.
46. El-Omar E.M., Penman I.D., Ardill J.E., et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995, 109(3):681-691.
47. Beales I., Blaser M.J., Srinivasan S., et al. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology 1997, 113(2):465-471.
48. Beales I.L. Effect of platelet-activating factor on gastrin release from cultured rabbit G-cells. Dig Dis Sci 2001, 46(2):301-306.
49. Corrigan M.A., Shields C.J., Keohane C., et al. The immunohistochemical demonstration of Helicobacter pylori in rectal ectopia. Surg Laparosc Endosc Percutan Tech 2009, 19(4):e146-e148.
50. Sonnenberg A., Lash R.H., Genta R.M. A national study of Helicobacter pylori infection in gastric biopsy specimens. Gastroenterology 2010, 139(6):1894-1901. e1892. [quiz: e1812].
51. Delaney B., McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005, 22(Suppl 1):32-40.
52. Loffeld R.J., Werdmuller B.F., Kuster J.G., et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000, 62(2/3):95-99.
53. Whiteman D.C., Parmar P., Fahey P., et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010, 139(1):73-83. [quiz: e11-72].
54. Forman D., Pisani P. Gastric cancer in Japan-honing treatment, seeking causes. N Engl J Med 2008, 359(5):448-451.
55. SEER Cancer Statistics Review, 1975-2007. 2011. Available at: Accessed February 18, 2011. http://seer.cancer.gov/csr/1975_2007.
56. Kamangar F., Dawsey S.M., Blaser M.J., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98(20):1445-1452.
57. Correa P., Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007, 133(2):659-672.
58. Fennerty M.B. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology 2003, 125(2):586-590.
59. Peura D.A., Haber M.M., Hunt B., et al. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol 2010, 44(3):180-185.
60. Asaka M., Kato M., Graham D.Y. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010, 15(6):486-490.
61. Wang C., Yuan Y., Hunt R.H. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007, 102(8):1789-1798.
62. Malfertheiner P., Sipponen P., Naumann M., et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005, 100(9):2100-2115.
63. Chey W.D., Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102(8):1808-1825.
64. Gonzalez C.A., Figueiredo C., Lic C.B., et al. Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol 2011, 106(5):867-874.
65. DuBois S., Kearney D.J. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005, 100(2):453-459.
66. Rostami N., Keshtkar-Jahromi M., Rahnavardi M., et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol 2008, 83(5):376-381.
67. Calvet X., Sanchez-Delgado J., Montserrat A., et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009, 48(10):1385-1391.
68. Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol 2003, 119(3):403-412.
69. Gisbert J.P., Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006, 101(4):848-863.
70. Genta R.M., Graham D.Y. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994, 40(3):342-345.
71. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20(10):1161-1181.
72. Stemmermann G.N. Intestinal metaplasia of the stomach. A status report. Cancer 1994, 74(2):556-564.
73. Rugge M., Farinati F., Baffa R., et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994, 107(5):1288-1296.
74. de Vries A.C., Haringsma J., de Vries R.A., et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010, 15(4):259-264.
75. Okubo M., Tahara T., Shibata T., et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion 2011, 83(3):161-166.
76. Tahara T., Shibata T., Nakamura M., et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 2009, 70(2):246-253.
77. Uedo N., Ishihara R., Iishi H., et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006, 38(8):819-824.
78. Wang A.Y., Patrie J.T., Cox D.G., et al. Single-operator experience in detecting gastritis, Helicobacter pylori infection, gastric intestinal metaplasia, and dysplasia before and after training in narrow-band imaging. Gastrointest Endosc 2010, 71:AB267.
79. Zhang J.N., Li Y.Q., Zhao Y.A., et al. Classification of gastric pit patterns by confocal endomicroscopy. Gastrointest Endosc 2008, 67(6):843-853.
80. Marchildon P., Balaban D.H., Sue M., et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Am J Gastroenterol 1999, 94(8):2105-2108.
81. Megraud F., Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007, 20(2):280-322.
82. Calvet X., Lehours P., Lario S., et al. Diagnosis of Helicobacter pylori infection. Helicobacter 2010, 15(Suppl 1):7-13.
83. 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004, 99(5):823-829.
84. Lin H.J., Lo W.C., Perng C.L., et al. Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. Helicobacter 2004, 9(6):663-668.
85. van Leerdam M.E., van der Ende A., ten Kate F.J., et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. Am J Gastroenterol 2003, 98(4):798-801.
86. Saad R.J., Chey W.D. Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what's next?. Clin Gastroenterol Hepatol 2008, 6(10):1086-1090.
87. Barkun A.N., Bardou M., Kuipers E.J., et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152(2):101-113.
88. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56(6):772-781.
89. O'Connor A., Gisbert J.P., McNamara D., et al. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010, 15(Suppl 1):46-52.
90. McMahon B.J., Hennessy T.W., Bensler J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003, 139(6):463-469.
91. Meyer J.M., Silliman N.P., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136(1):13-24.
92. Duck W.M., Sobel J., Pruckler J.M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004, 10(6):1088-1094.
93. Lee M., Kemp J.A., Canning A., et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999, 159(19):2312-2316.
94. Luther J., Higgins P.D., Schoenfeld P.S., et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010, 105(1):65-73.
95. Malfertheiner P., Bazzoli F., Delchier J.C., et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011, 377(9769):905-913.
96. Graham D.Y., Osato M.S., Hoffman J., et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000, 14(6):745-750.
97. Graham D.Y., Opekun A.R., Belson G., et al. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther 2005, 21(2):165-168.
98. Basu P.P., Rayapudi K., Pacana T., et al. A randomized open-label clinical trial with levofloxacin, omeprazole, Alinia® (nitazoxanide), and doxycycline (LOAD) versus lansoprazole, amoxicillin and clarithromycin (LAC) in the treatment naive Helicobacter pylori population. Am J Gastroenterol 2009, 104(Suppl 3):S404.
99. Molina-Infante J., Perez-Gallardo B., Fernandez-Bermejo M., et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010, 31(10):1077-1084.
100. Saad R.J., Schoenfeld P., Kim H.M., et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006, 101(3):488-496.
101. Sharara A.I., Chaar H.F., Aoun E., et al. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 2006, 11(4):231-236.
102. Chang W.L., Sheu B.S., Cheng H.C., et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009, 24(7):1230-1235.
103. van der Linden P.D., Sturkenboom M.C., Herings R.M., et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002, 324(7349):1306-1307. Clinical research ed.
104. van der Linden P.D., Sturkenboom M.C., Herings R.M., et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003, 163(15):1801-1807.
105. Webber M.A., Piddock L.J. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003, 51(1):9-11.
106. Murakami K., Fujioka T., Okimoto T., et al. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002, 19(1):67-70.
107. Wu D.C., Hsu P.I., Wu J.Y., et al. Randomized controlled comparison of sequential and quadruple (concomitant) therapies for H. pylori infection. Gastroenterology 2008, 134(Suppl 1). (4):A-24.
108. Gisbert J.P., Calvet X., O'Connor A., et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010, 44(5):313-325.
109. Romano M., Cuomo A., Gravina A.G., et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010, 59(11):1465-1470.
110. Kalach N., Serhal L., Bergeret M., et al. Arch Pediatr 2008, 15(2):200-201. [in French].
111. Park S., Chun H.J., Kim E.S., et al. The 10-day sequential therapy for Helicobacter pylori eradication in Korea: less effective than expected. Gastroenterology 2009, 136(Suppl 1):A-339-A-340.
112. Megraud F., Occhialini A., Rossignol J.F. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998, 42(11):2836-2840.
113. Gisbert J.P., Calvet X., Bujanda L., et al. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003, 8(2):90-94.
114. Van der Poorten D., Katelaris P.H. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007, 26(11/12):1537-1542.
115. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59(8):1143-1153.
116. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011, 8(2):79-88.
117. Leodolter A., Kulig M., Brasch H., et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001, 15(12):1949-1958.
118. Sharma V.K., Sahai A.V., Corder F.A., et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001, 15(12):1939-1947.
119. Ford A.C., Delaney B.C., Forman D., et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006, 2. CD003840.
120. Gisbert J.P., Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009, 30(8):791-815.
121. Jackson L., Britton J., Lewis S.A., et al. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009, 14(5):108-113.
122. Breckan R.K., Paulssen E.J., Asfeldt A.M., et al. The impact of body mass index and Helicobacter pylori infection on gastro-oesophageal reflux symptoms: a population-based study in Northern Norway. Scand J Gastroenterol 2009, 44(9):1060-1066.
123. Sykora J., Siala K., Varvarovska J., et al. Epidemiology of Helicobacter pylori infection in asymptomatic children: a prospective population-based study from the Czech Republic. Application of a monoclonal-based antigen-in-stool enzyme immunoassay. Helicobacter 2009, 14(4):286-297.
124. den Hoed C.M., van Eijck B.C., Capelle L.G., et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer 2011, 47(8):1211-1218.
125. Santos I.S., Boccio J., Davidsson L., et al. Helicobacter pylori is not associated with anaemia in Latin America: results from Argentina, Brazil, Bolivia, Cuba, Mexico and Venezuela. Public Health Nutr 2009, 12(10):1862-1870.
126. Jafri W., Yakoob J., Abid S., et al. Helicobacter pylori infection in children: population-based age-specific prevalence and risk factors in a developing country. Acta Paediatr 2010, 99(2):279-282.
127. Dube C., Nkosi T.C., Clarke A.M., et al. Helicobacter pylori antigenemia in an asymptomatic population of Eastern Cape Province, South Africa: public health implications. Rev Environ Health 2009, 24(3):249-255.
128. Shimoyama T., Oyama T., Matsuzaka M., et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter 2009, 14(2):87-90.
129. Zhang D.H., Zhou L.Y., Lin S.R., et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J 2009, 122(15):1759-1763.
130. Li Z., Zou D., Ma X., et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010, 105(12):2570-2577.